Skip to main content
Erschienen in: Clinical and Translational Oncology 2/2018

26.06.2017 | Brief Research Article

Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma

verfasst von: M. L. Sánchez de Molina, C. Díaz del Arco, P. Vorwald, D. García-Olmo, L. Estrada, M. J. Fernández-Aceñero

Erschienen in: Clinical and Translational Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Neoadjuvant therapy (NAT) is a useful therapeutic option. However, some patients respond poorly to it and can even show tumor progression. It is important to define factors that can predict response to NAT.

Materials and methods

This is a retrospective cohort study to define histopathological factors predicting response to NAT in gastric tubular carcinoma. This study has enrolled 80 patients receiving chemotherapy for locally advanced gastric carcinoma.

Results

44.5% of the patients were men; mean age was 64.49 years. Only 5.7% of the patients showed a complete response to therapy, 10% had grade 1, 21.4% grade 2, and 62.9% grade 3 regression. On follow-up, 43.8% of the patients showed recurrence of disease (57.1% distant metastasis) and 33.8% eventually died of it. We found a statistically significant association between response and prognosis. We found a statistically significant association between regression and perineural, vascular, and lymph vessel invasion. Logistic regression model showed that only lymph vessel invasion had independent influence. Lymph vessel invasion not only indicated lack of response to therapy, but also higher incidence of lymph node involvement in the gastrectomy specimen.

Discussion

Our study indicates that the presence of vascular or perineural invasion in the endoscopic biopsies and high histopathological grade predict poor response to therapy. This seems peculiar, for undifferentiated tumors are supposed to have better response to therapy.

Conclusion

Our study indicates that undifferentiated tumors respond worse to therapy. Furthermore, studies are necessary to define lack of response, to help avoid neoadjuvant therapy in unfavorable cases.
Literatur
1.
Zurück zum Zitat Salem ME, Hartley M, Unger K, Marshall JL. Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its future direction. Oncology (Williston Park). 2016;30:546–62. Salem ME, Hartley M, Unger K, Marshall JL. Neoadjuvant combined-modality therapy for locally advanced rectal cancer and its future direction. Oncology (Williston Park). 2016;30:546–62.
2.
Zurück zum Zitat Boland PM, Fakih M. The emerging role of neoadjuvant chemotherapy for rectal cancer. J Gastrointestinal Oncol. 2014;5:362–73. Boland PM, Fakih M. The emerging role of neoadjuvant chemotherapy for rectal cancer. J Gastrointestinal Oncol. 2014;5:362–73.
3.
Zurück zum Zitat Russell MC. Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer. J Surg Oncol. 2016;. doi:10.1002/jso.24293. Russell MC. Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer. J Surg Oncol. 2016;. doi:10.​1002/​jso.​24293.
5.
Zurück zum Zitat Metha RS. Response to neoadjuvant therapy and long-term survival in patients with triple negative breast cancer. J Clin Oncol. 2008;19:3286–8. Metha RS. Response to neoadjuvant therapy and long-term survival in patients with triple negative breast cancer. J Clin Oncol. 2008;19:3286–8.
6.
Zurück zum Zitat Gray J, Sommers E, Alvelo-Rivera M, Robinson L, Bepler G. Neoadjuvant therapy for resectable non-small cell lung cancer. Oncology (Willinston Park). 2009;23:879–86. Gray J, Sommers E, Alvelo-Rivera M, Robinson L, Bepler G. Neoadjuvant therapy for resectable non-small cell lung cancer. Oncology (Willinston Park). 2009;23:879–86.
7.
Zurück zum Zitat Shuberth CR, Bergquist JR, Groeschl RT, Habermann EB, Wilson PM, Truty MJ, et al. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: an intention to treat analysis of the National Cancer Database. Surgery. 2016;. doi:10.1016/j.surg.2016.06.010. Shuberth CR, Bergquist JR, Groeschl RT, Habermann EB, Wilson PM, Truty MJ, et al. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: an intention to treat analysis of the National Cancer Database. Surgery. 2016;. doi:10.​1016/​j.​surg.​2016.​06.​010.
8.
Zurück zum Zitat Kim SH, Chang HJ, Kim DY, Park JW, Baek JY, Kim SY, et al. What is the ideal regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Can Res Treat. 2016;48:998–1009.CrossRef Kim SH, Chang HJ, Kim DY, Park JW, Baek JY, Kim SY, et al. What is the ideal regression grading system in rectal cancer patients after preoperative chemoradiotherapy? Can Res Treat. 2016;48:998–1009.CrossRef
9.
Zurück zum Zitat Ryan JE, Warrier SK, Lynch AC, Ramsay RG, Phillips WA. Heriot AG predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2016;18(3):234–46. doi:10.1111/codi.13207.CrossRefPubMed Ryan JE, Warrier SK, Lynch AC, Ramsay RG, Phillips WA. Heriot AG predicting pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a systematic review. Colorectal Dis. 2016;18(3):234–46. doi:10.​1111/​codi.​13207.CrossRefPubMed
10.
Zurück zum Zitat Toxopeus EL, Nieboer D, Shapiro J, Biermann K, van der Gaast A, van Rij CM, et al. Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer. Radiother Oncol. 2015;115(3):392–8. doi:10.1016/j.radonc.2015.04.028 (Epub 2015 Ju).CrossRefPubMed Toxopeus EL, Nieboer D, Shapiro J, Biermann K, van der Gaast A, van Rij CM, et al. Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer. Radiother Oncol. 2015;115(3):392–8. doi:10.​1016/​j.​radonc.​2015.​04.​028 (Epub 2015 Ju).CrossRefPubMed
11.
Zurück zum Zitat Sun W, Li G, Wan J, Zhu J, Shen W, Zhang Z. Circulating tumor cells: a promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget. 2016;. doi:10.18632/oncotarget.10875. Sun W, Li G, Wan J, Zhu J, Shen W, Zhang Z. Circulating tumor cells: a promising marker of predicting tumor response in rectal cancer patients receiving neoadjuvant chemo-radiation therapy. Oncotarget. 2016;. doi:10.​18632/​oncotarget.​10875.
12.
Zurück zum Zitat Tromberg BJ, Zhang Z, Leproux A, O’Sullivan TD, Cerussi AE, Carpenter PM, et al. Predicting responses to neoadjuvant chemotherapy in Breast Cancer: ACRIN 6691 trial of diffuse optical spectroscopic imaging (DOSI). Cancer Res. 2016;76(20):5933–44.CrossRefPubMedPubMedCentral Tromberg BJ, Zhang Z, Leproux A, O’Sullivan TD, Cerussi AE, Carpenter PM, et al. Predicting responses to neoadjuvant chemotherapy in Breast Cancer: ACRIN 6691 trial of diffuse optical spectroscopic imaging (DOSI). Cancer Res. 2016;76(20):5933–44.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Gómez Del Pulgar T, Cebrián A, Fernández-Aceñero MJ, Borrero-Palacios A, Del Puerto-Nevado L, Martínez-Useros J, et al. Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer. J Cell Mol Med. 2016;20(9):1729–36. doi:10.1111/jcmm.12879 (Epub 2016 May 12).CrossRefPubMedPubMedCentral Gómez Del Pulgar T, Cebrián A, Fernández-Aceñero MJ, Borrero-Palacios A, Del Puerto-Nevado L, Martínez-Useros J, et al. Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer. J Cell Mol Med. 2016;20(9):1729–36. doi:10.​1111/​jcmm.​12879 (Epub 2016 May 12).CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Li S, Li J, Liu Z, Zhang Z, Zhang W, Yang H, et al. Predictive value of P53, Ki-67, HER2 protein detection in neoadjuvant chemotherapy for adenocarcinoma of gastroesophageal junction. Zhonghua Wei Chang Wai Ke Za Zhi. 2015;18(9):901–4.PubMed Li S, Li J, Liu Z, Zhang Z, Zhang W, Yang H, et al. Predictive value of P53, Ki-67, HER2 protein detection in neoadjuvant chemotherapy for adenocarcinoma of gastroesophageal junction. Zhonghua Wei Chang Wai Ke Za Zhi. 2015;18(9):901–4.PubMed
15.
Zurück zum Zitat Tang L, Li ZY, Li ZW, Zhang XP, Li YL, Li XT, et al. Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression. Clin Radiol. 2015;70(11):1198–204. doi:10.1016/j.crad.2015.06.083 (Epub 2015 Jul 15).CrossRefPubMed Tang L, Li ZY, Li ZW, Zhang XP, Li YL, Li XT, et al. Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression. Clin Radiol. 2015;70(11):1198–204. doi:10.​1016/​j.​crad.​2015.​06.​083 (Epub 2015 Jul 15).CrossRefPubMed
16.
17.
Zurück zum Zitat Figueiredo C, Camargo MC, Leite M, Fuentes-Pananá EM, Rabkin CS, Machado JC. Pathogenesis of gastric cancer: genetics and molecular classification. Curr Top Microbiol Immunol. 2017;400:277–304. doi:10.1007/978-3-319-50520-6-12.PubMed Figueiredo C, Camargo MC, Leite M, Fuentes-Pananá EM, Rabkin CS, Machado JC. Pathogenesis of gastric cancer: genetics and molecular classification. Curr Top Microbiol Immunol. 2017;400:277–304. doi:10.​1007/​978-3-319-50520-6-12.PubMed
18.
Zurück zum Zitat Neves Filho EH, de Sant’Ana RO, Nunes LV, Pires AP, da Cunha MD. Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. APMIS. 2017;125(2):79–84. doi:10.1111/apm.12642 (Epub 2017 Jan 2).CrossRefPubMed Neves Filho EH, de Sant’Ana RO, Nunes LV, Pires AP, da Cunha MD. Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. APMIS. 2017;125(2):79–84. doi:10.​1111/​apm.​12642 (Epub 2017 Jan 2).CrossRefPubMed
Metadaten
Titel
Histopathological factors predicting response to neoadjuvant therapy in gastric carcinoma
verfasst von
M. L. Sánchez de Molina
C. Díaz del Arco
P. Vorwald
D. García-Olmo
L. Estrada
M. J. Fernández-Aceñero
Publikationsdatum
26.06.2017
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 2/2018
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1707-1

Weitere Artikel der Ausgabe 2/2018

Clinical and Translational Oncology 2/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.